Abstract:Background/Aims: Since the first case of novel H7N9 infection was reported, China has experienced five epidemics of H7N9. During the fifth wave, a highly pathogenic H7N9 strain emerged. In order to assess whether the H7N9 vaccine based on A/Zhejiang/DTID-ZJU01/ 2013(H7N9) was effective in protecting against highly pathogenic H7N9, we conducted this study. Methods: Groups of mice were immunized twice by intraperitoneal injection with 500 mu l of either split vaccine alone or MF59- adjuvanted vaccine. Serum was collected 2 weeks after the second vaccine booster. The hemagglutinin inhibition test was conducted on vaccine seed and highly pathogenic H7N9 to evaluate the neutralization of highly pathogenic H7N9. We also immunized mice and challenged them with highly pathogenic H7N9. Mice were observed for illness, weight loss, and death at 1 week and 2 weeks post- infection. Then, the mice were sacrificed and lungs were removed. Antibody responses were assessed and pathological changes in the lung tissue were evaluated. Results: The ability of serum to neutralize highly pathogenic H7N9 was reduced. In mice, highly pathogenic H7N9 was more virulent than A/Zhejiang/DTID- ZJU01/2013(H7N9). After challenge with highly pathogenic H7N9, all mice died while mice challenged with A/Zhejiang/DTID- ZJU01/2013(H7N9) all recovered. The A/ZJU01/PR8/2013 split H7N9 avian influenza vaccine was able to protect against infection with highly pathogenic H7N9 in mice, with or without MF59. Moreover, H7N9 vaccine adjuvanted with MF59 produced high antibody levels, which lead to better protection. Conclusions: The A/ZJU01/PR8/2013 split H7N9 avian influenza vaccine based on A/Zhejiang/DTID- ZJU01/2013( H7N9) is effective in protecting against highly pathogenic H7N9. H7N9 vaccine adjuvanted with MF59 offers better protection against infection with highly pathogenic H7N9. In order to make the H7N9 vaccine applicable to humans, further clinical trials are required to evaluate MF59 adjuvanted vaccine. Meanwhile, the vaccine strain should be updated based on the highly pathogenic H7N9 gene sequence. (C) 2018 The Author(s) Published by S. Karger AG, Basel

Mouse Lung‐adapted Mutation of E190G in Hemagglutinin from H5N1 Influenza Virus Contributes to Attenuation in Mice

Amino Acid Substitutions HA A150V, PA A343T, and PB2 E627K Increase the Virulence of H5N6 Influenza Virus in Mice

Virulence of an H5N8 Highly Pathogenic Avian Influenza is Enhanced by the Amino Acid Substitutions PB2 E627K and HA A149V.

Adaptive Amino Acid Substitutions Enhance the Virulence of an Avian-Origin H6N1 Influenza Virus in Mice

Multiple Amino Acid Substitutions Involved in the Adaptation of Avian-Origin Influenza A (H10N7) Virus in Mice

Amino Acid Substitutions Involved in the Adaptation of a Novel H7N7 Avian Influenza Virus in Mice.

H5N1 Influenza A Virus with K193E and G225E Double Mutations in Haemagglutinin is Attenuated and Immunogenic in Mice.

Free energy simulations reveal a double mutant avian H5N1 virus hemagglutinin with altered receptor binding specificity.

Amino Acid Substitutions Involved in the Adaptation of a Novel Highly Pathogenic H5N2 Avian Influenza Virus in Mice

Pb1-Mediated Virulence Attenuation Of H5n1 Influenza Virus In Mice Is Associated With Pb2

Increased virulence of a novel reassortant H1N3 avian influenza virus in mice as a result of adaptive amino acid substitutions

Amino acid mutations PB1-V719M and PA-N444D combined with PB2-627K contribute to the pathogenicity of H7N9 in mice

Rapid Emergence of a PB2 D701N Substitution During Adaptation of an H9N2 Avian Influenza Virus in Mice

Mutual antagonism of mouse-adaptation mutations in HA and PA proteins on H9N2 virus replication

Multiple Amino Acid Substitutions Are Involved in the Adaptation of H9N2 Avian Influenza Virus to Mice.

Multiple amino acid substitutions involved in enhanced pathogenicity of LPAI H9N2 in mice.

139D in NS1 Contributes to the Virulence of H5N6 Influenza Virus in Mice

Key amino acid position 272 in neuraminidase determines the replication and virulence of H5N6 avian influenza virus in mammals

Amino Acid Substitutions Occurring During Adaptation of an Emergent H5N6 Avian Influenza Virus to Mammals.

The Protective Effects of the A/ZJU01/ PR8/2013 Split H7N9 Avian Influenza Vaccine Against Highly Pathogenic H7N9 in BALB/c Mice.

HA N193D substitution in the HPAI H5N1 virus alters receptor binding affinity and enhances virulence in mammalian hosts